LoQus23 Therapeutics
Developer of allosteric small molecule inhibitors targeting MSH3/MutSbeta designed to treat Huntington's disease and other triplet repeat neurodegenerative disorders. The company's therapeutics modula...
Valuation
$61.4M
Latest known
Share Price
N/A
Total Raised
$67.2M
Last Round
N/A